Early Discoveries, With More to Come So far, GLP-1s, first approved 20 years ago for type 2 diabetes and later obesity, have shown potential in treating a surprisingly wide range of conditions, such as heart disease, Parkinsons, Alzheimers, sleep apnea, and liver disease
Therefore, gene expression effects can be observed not (yet) affecting downstream phenotypic measures of toxicity
Why This Matters for Open Enrollment Conversations Open enrollment messaging often focuses on plan options, but affordability is the pressure point this year
Accumulating data showed a significant reduction of neurogenesis in the hippocampal region of both MDD patients and various MDD rodent models
The peptide cycle planning guide helps structure timing and transitions